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INTRODUCTION 
According to the Centers for Disease Control and Prevention, “Human Papillomavirus (HPV) 
is the most common sexually transmitted infection in the United States” (1). Other means of 
transfer of the virus have been noted, including transmission from mother to fetus (2,3) and 
transmission through oral-genital routes (4). These varying means of infection and the 
prevalence of infection make HPV a significant concern in pediatric and adolescent medicine 
(4).  
When infected, HPV may remain in quiescent stage and lead to asymptomatic expression or 
it may manifest with a self-limiting course with risk of differentiation to malignant state (5).
 
Pathological presentation of cervical cancer, genital warts, ano-genital cancer, and oro-
pharyngeal cancer are well described with HPV infection (6). The link between HPV and 
cervical cancer is well established and stronger than the link between smoking and lung 
cancer (6). Although there are ways to manage diseases related to HPV infection, there is no 
treatment for HPV infection itself. Thus, prevention via HPV vaccination is key to reducing 
HPV infections and associated diseases, especially cervical cancer, which is the third most 
common cancer in women in the United States (6). While cervical cancer only affects 
females, it is necessary to vaccinate males as well given that they can transmit HPV to 
females via sexual contact.   
In Kentucky, there is a low inclination for uptake (47.6% of females and 19% of males in 
Kentucky versus 57.3% of females and 34.6% of males nationally) (7) and adherence (26.8% 
of females in Kentucky versus 37.6% of females and 13.9% of males nationally) to HPV 
vaccine, even when it is free ( 8,9). Further evidence of relatively limited HPV prevention in 
the state of Kentucky is in the state’s cervical cancer rates. Kentucky exceeds the national 
average in cervical cancer rates (9.3 per 100,000 in Kentucky versus 7.4 per 100,000 
nationally) and ranks 5
th
 in the national in cervical cancer rates (8).  
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In the adolescent medicine clinic at the University of Kentucky, medical providers are 
working to address this national and local public health concern by encouraging all patients 
within the recommended age range (9-26) to start and finish the HPV vaccine series 
regardless of sex and sexual activity. The goal of this retrospective study is to determine if 
our vaccination rates exceed the local and national averages given our practices.  
METHODS 
We conducted a retrospective study in order to examine rates of vaccination in our clinic in 
an effort to evaluate our efforts in promoting HPV immunization. We included new 
adolescent patients between ages 9-26 seen in our facility from 10/2006-09/2015, with 
patients who had already begun the vaccine elsewhere excluded. Patients who had Medicaid 
and were 19 years of age or older were also excluded as Medicaid requires the vaccines to be 
administered at the Health Department. The total number of patients who met criteria was 
1423, which included 1014 females and 409 males. In addition, we always inquire about 
sexual activity in all patients which is standard of care. In this study we also analyzed sexual 
activity data at first injection. 
Our approach to vaccinations in our clinic is to review vaccine records for all patients during 
the first visit. We then council the patients and parents on importance of vaccines as disease 
prevention and public health issue, provide comprehensive verbal and written information on 
all vaccines and then all missing vaccines are offered. The message is: your child needs the 
following vaccines for reducing their chances of disease acquisition not just because of 
school requirement or lack thereof. We also use any patient visit, not just annual exams to 
address vaccine needs. Patients are given appointments for the next date to continue their 
vaccination and are reminded by phone 3 days prior to their appointment time. We do not 
single out HPV as an afterthought or in conjunction with sexual activity. 
The population of our clinic is not different than that of any primary care clinic because we 
do provide primary care as well as specialized care but the demographics and health of our 
patients is similar to that attending family medicine, internal medicine or pediatric clinics. 
RESULTS 
The study included 1423 eligible patients (1014 females and 409 males), as described above. 
Of these patients, 1010 females (99.6%) and 401 males (98%) started the HPV series of three 
vaccines and 562 females (55.4%) and 149 males (38.9%) completed the series (Table 1). 
These rates exceed local and national rates as depicted below. The average age at first 
injection was 14. At first injection 63.5% of patients reported no sexual activity. Data are not 
available for how man males finish the vaccine series in Kentucky.  
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Table 1 Rates of uptake and adherence to the HPV vaccine series in the clinic, state, and nation  
 Clinic 
% (n) 
Kentucky United States 
 Start Finish Start Finish Start Finish 
Female 99.6% 
(1010) 
55.4% 
(562) 
48% 27% 57% 38% 
Male 98% (401) 38.9% 
(159) 
19% n/a 35% 14% 
Source: State data obtained from "National, Regional, State, and Selected Local Area Vaccination Coverage Among 
Adolescents Aged 13–17 Years — United States, 2013." Centers for Disease Control and Prevention. Centers for Disease 
Control and Prevention, 25 July 2014. 
DISCUSSION 
As aforementioned, HPV associated cancer rates in Kentucky are amongst the highest 
compared to other states in the United States. Effective communication between medical 
providers, patients, and their parents are critical to improving vaccination uptake and 
adherence in Kentucky (9). In the adolescent medicine clinic at the University of Kentucky, 
our approach to HPV vaccination with patients and their parents has allowed us to begin 
vaccination with about 99% of eligible patients and complete vaccination with about 51% of 
eligible patients (as of data collection date, most are on track to complete their series) 
Rates of vaccination in our clinic far exceed local and national rates, especially for males. 
Compared to local and national data, twice as many females and three times as many males 
began the vaccination series. Compared to Kentucky, twice as many females completed the 
vaccination series. Data are not available for males who completed HPV vaccination in 
Kentucky; however, twice as many males completed the vaccine series in our clinic versus in 
the Unites States. 
Ideally, patients should receive the HPV vaccine prior to sexual activity given that HPV is 
transmitted primarily through sexual contact. For this reason, it is recommended that patients 
start vaccination by age 11 or 12 (9). The average age at first injection in our clinic was 14, 
leaving room for improvement. Moreover, about 46% of our patients report engaging in 
sexual activity prior to beginning vaccination.    
Vaccination in patients who already are sexually active is still effective in preventing the 
virus types of the vaccine even if the patient has acquired one type, the vaccine can still 
prevent the other as indicated by the Food and Drug approval and the vaccine package insert. 
Our goal is to follow the steps outlined below in order to improve vaccination rates prior to 
sexual activity, further preventing the incidence of cervical and other cancers in our patient 
and local population.  
CONCLUSION 
With the higher rates of HPV vaccination observed in our clinic compared to that of the state 
and the United States, we feel that implementing the following methods to increase 
vaccination rates in local and national pediatric clinics works. 
Step 1: Educate parents and patients on HPV and its potential effects and offer it as part of needed 
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vaccines not an afterthought. 
Step 2: Encourage vaccination at each visit, highlighting the benefits and limited risks of acquiring the 
vaccine. 
Step 3: Incorporation of patient-centered reminders, and commendation for beginning the series. 
Step 4: Continue further reinforcement throughout the course and recapitulate the importance of 
completing the vaccination. 
 
Although these will require consistency in health care provider efforts, the benefits we 
anticipate are invaluable to the population. We envision that our approach, if implemented 
within the state as a whole, will lead to increasing HPV vaccination and a corresponding 
decline in the prevalence of the HPV related pathology in Kentucky. 
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